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Antiphospholipid syndrome is a rare disorder. Acute myocardial infarction is uncommon among these patients. Here we report a
case of a 44-year-old man with antiphospholipid syndrome admitted for acute inferior myocardial infarction. Performed coronary
angiography revealed that both the right coronary and the left circumﬂex coronary arteries were occluded by thrombi. We
successfullyperformedprimaryangioplastyandstentimplantationforbothoftheoccludedcoronaryarteries.Intheliterature,this
is the ﬁrst case with antiphospholipid syndrome in which primary coronary angioplasty with stent implantation was successfully
performed for two coronary arteries with acute thrombotic occlusion.
1.Background
Antiphospholipid syndrome is a thrombotic disorder char-
acterised by antiphospholipid antibodies. Clinical features
are thrombosis, thrombocytopenia, and recurrent fetal loss
[1]. This syndrome has the clinical manifestations of
systemic thrombotic disorders, including recurrent deep
vein thromboses, pulmonary thromboembolisms, and brain
strokes. Antiphospholipid syndrome has systemic vascular
thromboticmanifestationsandthesethrombosesoftenoccur
and recur in multiple organs. Coronary events have been
describedtooccurinapproximately5%ofpatientswithAPS,
especially patients under age 45 [2].
The diagnosis of antiphospholipid syndrome is deﬁned
by the Sapporo criteria which were recently revised. These
criteria require a clinical manifestation of one or more
episodes of thrombosis or thrombotic-related events and
thelaboratoryconﬁrmationofanantiphospholipidantibody
on two or more occasions at least 12 weeks apart. Notably,
thrombotic events related to pregnancy, such as unexplained
fetal loss or premature births related to preeclampsia,
eclampsia, or placental insuﬃciency, are important clinical
criteria. There are two basic types of antiphospholipid
antibodies: the anticardiolipins (ACL) and the anticoagulant
antibodies (LAC). The rationale for the time limitations
on the presence of antiphospholipid antibodies comes from
the fact that there are such antibodies present, frequently
transiently, in up to 4%-5% of otherwise healthy individuals.
They can also be seen in the setting of many infectious dis-
eases, such as mumps, rubella, and malaria. Approximately
one third of patients with systemic lupus erythematosus
(SLE) have an antiphospholipid antibody. Not all antiphos-
pholipid antibodies in the general population cause throm-
botic complications. Approximately 50%–70% of patients
with SLE with antiphospholipid antibodies will develop
antiphospholipid syndrome. The incidence of antiphospho-
lipid syndrome in patients without SLE is not well estab-
lished. The characteristics that are linked to higher throm-
botic complications include higher antibody titers, presence
of the LAC antibody, and a history of thrombosis [3–8].2 Case Reports in Medicine
Figure 1: Occluded right coronary artery by trombi.
Althoughpatientswithantiphospholipidsyndromeoften
exhibit positive lupus anticoagulant activity, they uncom-
monly present the typical clinical ﬁndings of SLE which are
diagnostic. Thus, antiphospholipid syndrome without the
clinical features of SLE is called primary antiphospholipid
syndrome [9].
Acute myocardial infarction is not common among
patients with this syndrome. In the literature, there are cases
that are successfully treated by thrombolytic therapy, balloon
angioplasty, and stenting but there is not enough experience
about thrombus aspiration [10]. Here we report a case of a
44-year-old man with antiphospholipid syndrome admitted
for acute inferior myocardial infarction. He did not have
major traditional risk factors except that he smoked ﬁve
cigarettes a day.
2.CaseReport
The patient admitted to the emergency service with typi-
cal chest pain persisting for 3 hours. Electrocardiography
demonstrated >2mm ST segment elevation in inferior leads.
He was immediately transferred to the catheter laboratory
for a primary angioplasty. Performed coronary angiography
revealed that both the right coronary and the left circumﬂex
coronary arteries were occluded by thrombi (Figures 1 and
2).
Antiphospholipid syndrome was remarkable in his med-
icalhistory.Hewasdiagnosedasantiphospholipidsyndrome
eight years ago after two attacks of deep vein thrombosis
with positive anticardiolipin antibody. After this attack, he
wasfollowedatarheumotologyclinicandhisanticardiolipin
antibody was still positive at the third month, ﬁrst and
second years of the initial diagnosis. Proper anticoagulant
treatment was given at that time. There was no positive
family history of thoromboss and the patient did not
have any other manifestations of antiphospholipid antibody
syndromeafterthesetwoattacks.However,hestoppedtaking
warfarin 6 weeks ago due to a dental procedure and delayed
to initiate warfarin therapy after his dental treatment was
Figure 2: Occluded left circumﬂex coronary artery by trombi.
completed. The INR level was less than 1.6 during this dental
procedure.
Primary angioplasty and stent implantation for both the
right coronary and the left circumﬂex coronary arteries were
successfully performed. After stent implantation, coronary
blood ﬂow was TIMI III grade within both arteries (Figures
3 and 4).
In coronary care unit, intravenous heparin infusion was
performed for the next 24 hours followed by warfarin (5mg
daily). The patient also received clopidogrel (75mg daily
following a 600mg loading dose), aspirin (300mg daily),
metoprolol (50mg daily), atorvastatin (20mg daily), and
ramipril (2.5mg daily) after stent implantation.
Thepatientwasconsultedwithrheumotologyandhema-
tology clinic in coronary care unit and the anticardiolipin
antibody was positive.
Echocardiograpic examination did not reveal an intrac-
ardiac thrombus that could be a source for coronary
embolism. Inferior and lateral wall segments of the left
ventricle were moderately hypokinetic. Ejection fraction was
50% and there was mild mitral regurgitation.
After a four-day period, the patient was discharged from
the hospital on clopidogrel (75mg daily), warfarin (5mg
daily), metoprolol (50mg daily), atorvastatin (20mg daily),
and ramipril (2.5mg daily) therapy. INR level was 2.3 at
the time of discharge. The patient was called for routine
follow-up controls at the third and sixth months, he was
followed up by rheumotology and hematology clinics. He
was asymptomatic and had a negative exercise stress test at
hissixthmonthoffollowup;therefore,coronaryangiography
was not performed. Also the anticardiolipin antibody was
positive at sixth month.
3. Discussion
The most common clinical features of antiphospholipid
syndrome are recurrent arterial or venous thrombotic events
such as deep vein thrombosis, pulmonary thromboem-
bolism, and stroke. However, coronary embolism due toCase Reports in Medicine 3
Figure 3: Right coronary artery angiogram after successful stent
implantation.
Figure 4: Left circumﬂex coronary artery angiogram after success-
ful stent implantation.
t h i ss y n d r o m ei sn o tc o m m o n[ 11]. Thus antiphospholipid
syndrome may cause acute myocardial infarction due to
thrombotic occlusion of coronary arteries. Since it is orig-
inated from a thrombotic occlusion, thrombolytic therapy
was reported to be a rationale treatment option for such
cases in the literature [12–14]. However, primary coronary
angioplasty and stent implantation are currently an eﬀective
way of myocardial revascularization by opening an infarct
related artery and it is the treatment of choice in deﬁnite
clinicalcircumstances.Intheliterature,therewereafewcases
of antiphospholipid syndrome that were treated by coronary
angioplasty in the setting of acute myocardial infarction
until the year 1998 but the results were not successful [15].
The ﬁrst successful primary angioplasty was reported by
Takeuchi et al. in 1998 in a patient with antiphospholipid
syndrome. Jankowski et al. reported the ﬁrst successful stent
implantation in patient with antiphospholipid syndrome
in the same year [16]. In the year 2004, Prokop et al.
reported the ﬁrst patient with antiphospholipid syndrome
presenting with acute myocardial infarction that was related
to the thrombotic occlusion of two coronary arteries like
in our case. In that case, both the left anterior descending
and circumﬂex coronary arteries were occluded [17]. They
becameobligatedtoperformthrombolytictherapyfollowing
the failure of primary angioplasty.
Since stent implantation may probably trigger acute
thrombosis in patient with antiphospholipid syndrome, only
the balloon dilatation of the lesion may be an alternative
choice. Also, thrombectomy aspiration device could have
been an alternative catheter to stent implantation or an
adjunctive catheter for baloon angioplasty without stenting.
Tamhene et al. found that thrombectomy devices appear
to improve markers of myocardial perfusion in patients
undergoing primary percutaneous coronary interventions,
with no diﬀerence in overall 30-day mortality but an
increased likelihood of stroke [18]. Using thrombectomy
aspiration device for better clinical outcome is only an
assumption for this case. After baloon angioplasty, we had to
implant stents in order to avoid restenosis and also because
of the irregular vessel wall image in angiograms. Since the
risk of thrombosis increases with fresh metal from a stent,
antithrombotic therapy following stent implantation gains
importance in such patients. In our case, we initiated acetyl-
salicylic acid, clopidogrel, and heparin infusion to prevent
acute thrombosis. Use of glycoprotein IIb/IIIa inhibitors that
are recommended following primary coronary angioplasty
for ST elevated myocardial infarction might be used as an
adjunctive treatment. However, we do not have enough
experience in cases with antiphospholipid syndrome.
It seems that this is the ﬁrst case in which primary
coronary angioplasty with stent implantation was suc-
cessfully performed to total occlusions in two coronary
arteries induced by antiphospholipid syndrome. Although
the balloon dilatation may seem rationale, we successfully
performed stent implantation in this patient. As a conclu-
sion it is very important to initiate and to maintain the
antithrombotic drug therapy following coronary angioplasty
and stent implantation in patients with antiphospholipid
syndrome.
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